Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
NCT03760523Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2019
- Primary completion
- Oct 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of minnelide in acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicities at 28 days. Started Apr 2019; status: terminated.
02
Drugs
minnelide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03760523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760523.